BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
7/5/2017 4:40:07 AM | Browse: 452 | Download: 415
Publication Name World Journal of Hepatology
Manuscript ID 33313
Country/Territory United States
2017-02-07 10:41
Peer-Review Started
2017-02-07 14:35
To Make the First Decision
2017-03-27 11:23
Return for Revision
2017-03-28 15:48
2017-04-06 07:58
Second Decision
2017-04-24 17:55
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2017-05-05 16:44
Articles in Press
2017-05-05 16:44
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2017-06-05 06:15
Publish the Manuscript Online
2017-07-05 04:40
ISSN 1948-5182 (online)
Open Access This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Gastroenterology and Hepatology
Manuscript Type Minireviews
Article Title Opportunities for treatment of the hepatitis C virus-infected patient with chronic kidney disease
Manuscript Source Invited Manuscript
All Author List Marco Ladino, Fernando Pedraza and David Roth
Funding Agency and Grant Number
Corresponding author David Roth, MD, Katz Family Division of Nephrology and Hypertension, University of Miami, 1120 N.W. 14th Street, Room 813, Miami, FL 33136, United States. d.roth@med.miami.edu
Keywords Hepatitis C virus; Chronic kidney disease; Direct acting antiviral agents; Kidney transplantation
Core Tip Advances in the understanding of the molecular biology of hepatitis C virus (HCV) have ushered in a new era in treatment. Recent studies have shifted the focus to the more difficult-to-treat cohorts of patients. The presence of chronic kidney disease and end stage renal disease were exclusion criteria for the pivotal clinical direct-acting antiviral agents trials, creating a group of patients with a large unmet medical need. This review will update the reader on the use of the direct acting antiviral agents in the HCV-infected patient with kidney disease. Recommendations for the timing of therapy, choice of agents and management of the kidney transplant candidate will be presented.
Publish Date 2017-07-05 04:40
Citation Ladino M, Pedraza F, Roth D. Opportunities for treatment of the hepatitis C virus-infected patient with chronic kidney disease. World J Hepatol 2017; 9(19): 833-839
Url http://www.wjgnet.com/1948-5182/full/v9/i19/833.htm
DOI http://dx.doi.org/10.4254/wjh.v9.i19.833
Full Article (PDF) WJH-9-833.pdf
Full Article (Word) WJH-9-833.doc
Manuscript File 33313-Review.docx
Answering Reviewers 33313-Answering reviewers.pdf
Audio Core Tip 33313-Audio core tip.mp3
Conflict-of-Interest Disclosure Form 33313-Conflict-of-interest statement.pdf
Copyright License Agreement 33313-Copyright assignment.pdf
Peer-review Report 33313-Peer-review(s).pdf
Scientific Misconduct Check 33313-Scientific misconduct check.pdf
Scientific Editor Work List 33313-Scientific editor work list.pdf